REG - EKF Diagnostics Hldg - Share Buyback

EKF Diagnostics HoldingsAnnouncement

02/04/2025 07:04

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250402:nRSB2447Da&default-theme=true

RNS Number : 2447D  EKF Diagnostics Holdings PLC  02 April 2025

 

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Share Buyback

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics
business, announces that it has purchased a total of 141,693 of its ordinary
shares of 1p each in the capital of the Company ("Ordinary Shares") at a
weighted average price of 22.5 pence per share. The Ordinary Shares purchased
will be held in treasury.

 

Aggregated information

 

 Date of purchase                       1 April 2025
 Number of Ordinary Shares purchased    141,693
 Highest price paid per Ordinary Share  22.5p
 Lowest price paid per Ordinary Share   22.5p
 Volume weighted average price paid     22.5p

 

 Transaction details

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market
Abuse Regulation) (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018), a detailed breakdown of individual
trades is available below:

 

 Number of Ordinary Shares purchased  Transaction price (GBp)  Time of transaction  Trading venue
 100,000                              22.5p                    09:21:53             AIMX
 41,693                               22.5p                    16:05:33             AIMX

 

Total voting rights

 

Following the purchase, the Company's total issued share capital will consist
of 454,930,564 Ordinary Shares each carrying one voting right, of which
2,041,693 Ordinary Shares are held in treasury. Therefore, the total number of
Ordinary Shares carrying voting rights will be 452,888,871. This figure may be
used by shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or a change
to their interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.

 

PDMR dealing

 

As part of the buyback and within the above aggregate purchase, EKF acquired
41,693 Ordinary Shares at a price 22.5 pence per Ordinary Share from Harwood
as investment manager to Oryx. Harwood has facilitated this transaction solely
in order to ensure that the aggregate indirect beneficial interest of Mr.
Mills remains at approximately the same level and in any event does not exceed
30% of the prevailing total voting rights in the Company following any
repurchases.

 

Following the above sale of Ordinary Shares by Oryx to the Company, Mr. Mills'
aggregate indirect interest in the Company is 133,552,347 Ordinary Shares.

 

Additional disclosures relating to this PDMR dealing are detailed below.

 

 

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018).

 

 

The person responsible for arranging the release of this Announcement

on behalf of the Company is Julian Baines, Executive Chair.

 

 

 EKF Diagnostics Holdings plc                                www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Julian Baines, Executive Chair                               via Walbrook PR
 Gavin Jones, Chief Executive Officer
                                                                                           Tel: +44 (0)20 7496 3000

 Singer Capital Markets (Nominated Adviser & Broker)
 Phil Davies / Oliver Platts

 Walbrook PR Limited              Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Alice Woodings    Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

 

EKF is an AIM-listed global diagnostics business focussed on:

 

 ●    Point-of-Care analysers in the key areas of Hematology and Diabetes
 ●    Life Sciences services provide specialist manufacture of enzymes and custom
      products for use in diagnostic, food and industrial applications.

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing
sites across the US and Germany, selling into over 120 countries world-wide.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Christopher Mills

 2    Reason for the notification

 a)   Position/status                                              Non-Executive Director

 b)   Initial notification /Amendment                              Initial Notification

 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 a)   Name                                                         EKF Diagnostics Holdings plc
 b)   LEI                                                          213800DXTF3EAUK1AR05

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 1 pence each

      Identification code                                          GB0031509804

 b)   Nature of the transaction                                    Disposal of Ordinary Shares

 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     22.5p             41,693

 d)   Aggregated information

      - Aggregated volume                                          n/a

      - Price

 e)   Date of the transaction                                       1 April 2025

 f)   Place of the transaction                                     London Stock Exchange, AIMX

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSSSAEFFEISEFL